Associations between mRNA COVID-19 vaccination and urticaria: a nationwide registry-based cohort study in Denmark.

IF 2.6 3区 医学 Q2 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
Elena Dudukina, Elvira V Brâuner, CæcilieB Christiansen, Stine H Mogensen, Mona E Hervig, Stine Ulsø, Martin Z Larsen
{"title":"Associations between mRNA COVID-19 vaccination and urticaria: a nationwide registry-based cohort study in Denmark.","authors":"Elena Dudukina, Elvira V Brâuner, CæcilieB Christiansen, Stine H Mogensen, Mona E Hervig, Stine Ulsø, Martin Z Larsen","doi":"10.1177/14034948251333901","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To investigate the association between mRNA COVID-19 vaccination and the risk of urticaria.</p><p><strong>Study design: </strong>Nationwide observational cohort study.</p><p><strong>Setting: </strong>Healthcare registers in Denmark.</p><p><strong>Participants: </strong>The vaccinated cohort included Danish residents aged ⩾5 years who received at least one dose of Comirnaty (Pfizer-BioNTech, BNT) or Spikevax (Moderna, MOD) in December 2020 to July 2023; the pre-pandemic (2017-19) general population aged ⩾5 years formed the comparator cohort.</p><p><strong>Methods: </strong>Urticaria-free participants were followed from the vaccination date until the earliest of the incident chronic or other types of urticaria diagnosis, COVID-19 infection, end of the 90-day outcome risk window, death, emigration, or October 2023. The expected number of urticaria events was computed using indirect standardisation of the pre-pandemic urticaria incidence rates. Standardised incidence ratios (SIRs) with corresponding 95% confidence intervals (CIs) were calculated overall and across sex, age and vaccine sequence-specific strata.</p><p><strong>Results: </strong>We ascertained 4,700,301 vaccinated and 5,480,146 pre-pandemic comparators. Following all vaccine product sequences, SIRs (95% CI) were 0.83 (0.71-0.96) for chronic urticaria and 1.14 (95% CI 1.03-1.25) for other types of urticaria. Among MOD schedule adherers, the risk was three to fourfold increased for chronic (SIR 3.00, 95% CI 2.27-3.88) and other types of urticaria (SIR 3.65, 95% CI 3.06-4.31). Sensitivity analyses of dose specific effects confirmed a fourfold increased risk after MOD vaccine sequence but not BNT.</p><p><strong>Conclusions: </strong>Following the most recent mRNA vaccination dose, MOD vaccine schedule adherers had a higher than expected incidence of chronic and other types of urticaria. We found no association between BNT vaccination schedule and increased risk of urticaria.</p>","PeriodicalId":49568,"journal":{"name":"Scandinavian Journal of Public Health","volume":" ","pages":"14034948251333901"},"PeriodicalIF":2.6000,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Scandinavian Journal of Public Health","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/14034948251333901","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: To investigate the association between mRNA COVID-19 vaccination and the risk of urticaria.

Study design: Nationwide observational cohort study.

Setting: Healthcare registers in Denmark.

Participants: The vaccinated cohort included Danish residents aged ⩾5 years who received at least one dose of Comirnaty (Pfizer-BioNTech, BNT) or Spikevax (Moderna, MOD) in December 2020 to July 2023; the pre-pandemic (2017-19) general population aged ⩾5 years formed the comparator cohort.

Methods: Urticaria-free participants were followed from the vaccination date until the earliest of the incident chronic or other types of urticaria diagnosis, COVID-19 infection, end of the 90-day outcome risk window, death, emigration, or October 2023. The expected number of urticaria events was computed using indirect standardisation of the pre-pandemic urticaria incidence rates. Standardised incidence ratios (SIRs) with corresponding 95% confidence intervals (CIs) were calculated overall and across sex, age and vaccine sequence-specific strata.

Results: We ascertained 4,700,301 vaccinated and 5,480,146 pre-pandemic comparators. Following all vaccine product sequences, SIRs (95% CI) were 0.83 (0.71-0.96) for chronic urticaria and 1.14 (95% CI 1.03-1.25) for other types of urticaria. Among MOD schedule adherers, the risk was three to fourfold increased for chronic (SIR 3.00, 95% CI 2.27-3.88) and other types of urticaria (SIR 3.65, 95% CI 3.06-4.31). Sensitivity analyses of dose specific effects confirmed a fourfold increased risk after MOD vaccine sequence but not BNT.

Conclusions: Following the most recent mRNA vaccination dose, MOD vaccine schedule adherers had a higher than expected incidence of chronic and other types of urticaria. We found no association between BNT vaccination schedule and increased risk of urticaria.

mRNA COVID-19疫苗接种与荨麻疹之间的关系:丹麦一项基于全国登记的队列研究
目的:探讨新冠肺炎疫苗接种mRNA与荨麻疹发病风险的关系。研究设计:全国观察队列研究。环境:丹麦的医疗保健登记处。参与者:接种疫苗的队列包括在2020年12月至2023年7月期间接受至少一剂Comirnaty (Pfizer-BioNTech, BNT)或Spikevax (Moderna, MOD)的小于5岁的丹麦居民;大流行前(2017-19年)年龄大于或等于5岁的一般人群形成了比较队列。方法:无荨麻疹的参与者从接种疫苗之日起进行随访,直到最早发生慢性或其他类型荨麻疹诊断、COVID-19感染、90天结局风险窗口结束、死亡、移民或2023年10月。使用大流行前荨麻疹发病率的间接标准化计算预期的荨麻疹事件数。标准化发病率(SIRs)与相应的95%置信区间(CIs)被计算在整体和跨性别、年龄和疫苗序列特异性阶层。结果:我们确定了4,700,301名接种疫苗者和5,480,146名大流行前比较者。在所有疫苗产品序列中,慢性荨麻疹的SIRs (95% CI)为0.83(0.71-0.96),其他类型荨麻疹的SIRs为1.14 (95% CI 1.03-1.25)。在MOD时间表坚持者中,慢性荨麻疹(SIR 3.00, 95% CI 2.27-3.88)和其他类型荨麻疹(SIR 3.65, 95% CI 3.06-4.31)的风险增加了三到四倍。剂量特异性效应的敏感性分析证实,接种MOD疫苗后风险增加4倍,而接种BNT疫苗后风险增加4倍。结论:在最近的mRNA疫苗接种剂量后,MOD疫苗计划依从者的慢性和其他类型荨麻疹的发病率高于预期。我们发现BNT疫苗接种计划与荨麻疹风险增加之间没有关联。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Scandinavian Journal of Public Health
Scandinavian Journal of Public Health 医学-公共卫生、环境卫生与职业卫生
CiteScore
6.50
自引率
2.90%
发文量
135
审稿时长
4-8 weeks
期刊介绍: The Scandinavian Journal of Public Health is an international peer-reviewed journal which has a vision to: publish public health research of good quality; contribute to the conceptual and methodological development of public health; contribute to global health issues; contribute to news and overviews of public health developments and health policy developments in the Nordic countries; reflect the multidisciplinarity of public health.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信